Maintenance of Androgen Receptor Inactivation by S-Nitrosylation
- 14 November 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (22) , 6690-6699
Abstract
Antiandrogens target ligand-binding domain of androgen receptor (AR) and are used as first-line therapeutics to treat patients diagnosed with locally advanced and metastatic prostate cancer. Although initially beneficial as judged with actual tumor mass shrinkage, this therapy invariably fails and the cancer reappears as castration-resistant disease. Here, we report that increased intracellular nitric oxide (NO) levels lead to growth inhibition of both androgen-dependent and castration-resistant prostate tumors through a mechanism that involves AR function inactivation by S-nitrosylation of a single C601 residue present in the DNA-binding domain. AR S-nitrosylation does not impact its subcellular distribution but attenuates its ability to bind AR-responsive elements in promoter region of target genes. Mechanistically, AR is transnitrosylated by its partner HSP90 protein. Ubiquitous small-molecule NO donors promote the AR S-nitrosylation and inhibit growth of castration-resistant prostate tumors. These findings reveal a new mechanism of regulating AR function and suggest that sequential targeting of distinct domains of AR may extend therapeutic efficacy for patients with advanced prostate cancer. Cancer Res; 73(22); 6690–9. ©2013 AACR.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate CancerCurrent Treatment Options in Oncology, 2012
- Proteomic Characterization of the Cellular Response to Nitrosative Stress Mediated by S-Nitrosoglutathione Reductase InhibitionJournal of Proteome Research, 2012
- Membrane transfer of S-nitrosothiolsNitric Oxide, 2011
- GAPDH mediates nitrosylation of nuclear proteinsNature Cell Biology, 2010
- Transnitrosylation of XIAP Regulates Caspase-Dependent Neuronal Cell DeathMolecular Cell, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Phase II Study of Nitric Oxide Donor for Men With Increasing Prostate-specific Antigen Level After Surgery or Radiotherapy for Prostate CancerUrology, 2009
- Protein S-nitrosylation in health and disease: a current perspectiveTrends in Molecular Medicine, 2009
- Identification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancerProceedings of the National Academy of Sciences, 2009
- Targeting the androgen receptor pathway in prostate cancerCurrent Opinion in Pharmacology, 2008